Document:

EX-10.32

 Exhibit 10.32 

CONSENT AND ACKNOWLEDGEMENT OF PAYMENT DIRECTION 
 November 20, 2012 
 Genentech, Inc. 
 1 DNA Way 
 South San Francisco, CA 94080 
 Attn: Global Head, Alliance and Asset Management 
 Fax No.: (650) 467-3294 

 

	Re:	Collaborative Research, Development and License Agreement: Consent and Payment Direction 

 Ladies and Gentlemen: 
 As we have discussed, Curis, Inc., a Delaware corporation
(“Curis”), is in the process of discussing, under confidentiality agreements, a potential provision of debt financing (the “Transaction”) to Curis by Biopharma Secured Debt Fund II Sub, S. à r.
1., a Luxembourg limited liability company or affiliates thereof (the “Investor”), where the debt would be secured by Curis’ rights to receive certain payments under that certain Collaborative Research, Development and
License Agreement, dated as of June 11, 2003, by and between Curis and Genentech, Inc. (“Genentech”), as amended as of December 10, 2004, April 11, 2005, May 8, 2006 and again as of
April 26, 2012 (the “License Agreement”). In connection with the Transaction, by this letter agreement (“Letter Agreement”), Curis is seeking Genentech’s consent under Section 16.8 of
the License Agreement to the assignment of certain rights to receive payments described in the License Agreement and pledge of such rights, as well as the disclosure of certain Confidential Information under the License Agreement, each as more fully
described herein. Defined terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. 
 Consent to
Assignment of and Pledge of Certain Rights Under the License Agreement 
 By its acknowledgement and agreement below, Genentech hereby
consents to: (i) the sale, conveyance, transfer and assignment by Curis to Curis Royalty LLC, a wholly-owned, newly-established subsidiary of Curis (the “Borrower”) of all of Curis’ right, title and interest in and
to: (a) the royalty payments specified in Section 8.5 of the License Agreement (including late payments thereof, if any); (b) any amounts payable under Section 9.4 of the License Agreement with respect to the underpayment of any
such royalties payable under Section 8.5 of the License Agreement (excluding the out-of-pocket costs of the auditing party in connection with any such audit that are payable by Genentech, if any); (c) any indemnity payments payable under
Section 14.1(b) of the License Agreement with respect to Losses (as defined in the License Agreement) suffered by the Borrower with respect to amounts payable under Sections 8.5, 9.3 or 9.4 of the License Agreement; and (d) any interest
payable under Section 9.3 of the License Agreement with respect to the late payment of any such royalties, underpayments, indemnity payments or interest thereon (collectively, the “Subject Payments”); (ii) the
pledge by the Borrower to the Investor of such existing rights to receive the Subject Payments as security for the debt issued by 

  
 1 

 
the Borrower to the Investor, pursuant to the terms of the Transaction (including, for the avoidance of doubt, the actions taken by the Investor to perfect a first priority security interest in
favor of the Investor in all such rights); and (iii) the potential transfer of such existing rights to the Investor as the pledgee or potential successor-in-interest of such rights, pursuant to the terms of the Transaction, solely in connection
with the exercise by the Investor of its rights and remedies upon an Event of Default (as defined in that certain Credit Agreement executed by Curis, the Borrower and the Investor in furtherance of the Transaction). 

Genentech gives the foregoing consents, provided that, absent further written consent by Genentech, which shall not be unreasonably withheld,
conditioned or delayed, (i) the Borrower shall not further sell, convey, transfer or assign the right, title and interest in and to the Subject Payments and (ii) the Investor shall not further pledge or transfer such rights to receive the
Subject Payments; provided, however, that the Investor may further transfer such rights, solely in connection with the exercise by the Investor of its rights and remedies upon an Event of Default, to a transferee that has entered into
a confidentiality agreement with Genentech, in form and substance reasonably acceptable to Genentech (provided that such confidentiality agreement shall be on terms substantially similar to the provisions of the following section of this
Letter Agreement (Consent to Disclosure of Certain Confidential Information)), and that, in such confidentiality agreement, such transferee represents and warrants that it (x) does not conduct scientific research or engage in development
activities with respect to diagnostic or therapeutic products in the biotechnology or pharmaceutical industries; (y) does not manufacture, promote, market, distribute or sell any diagnostic or therapeutic products in the biotechnology or
pharmaceutical industries; and (z) does not control, is not controlled by and is not under common control with any person or entity that conducts any of the activities in the foregoing clauses (x) and (y). In the event Genentech’s
further written consent(s) is required and granted hereunder, the rights of any third party to receive any Confidential Information of Genentech shall be subject to the provisions of the following section of this Letter Agreement (Consent to
Disclosure of Certain Confidential Information), as applicable to the Borrower and the Investor (as the case may be) mutatis mutandis. 

Consent to Disclosure of Certain Confidential Information 
 In connection with Curis’ current rights to receive payments specified in the License Agreement (including the Subject Payments), Curis has received and is entitled to receive in the future certain
information regarding Products as specified in the License Agreement, including worldwide Net Sales of Lead Products and royalty payment reductions applicable to Lead Products (if any), which may constitute Confidential Information of Genentech. In
connection with, and solely for purposes of, the sale, conveyance, transfer and assignment by Curis to the Borrower of all of Curis’ right, title and interest in and to the Subject Payments, Curis requests Genentech’s consent to
Curis’ disclosure to the Borrower of all reports, accountings, statements, data, certificates, documents and other Confidential Information of Genentech required or contemplated by, or otherwise delivered pursuant to Sections 9.1, 9.3 and 9.4
of the License Agreement. In addition, the Borrower (or Curis on the Borrower’s behalf) proposes to disclose such Confidential Information to the Investor and a bank or similar entity serving as an escrow agent with respect to the debt issued
in the Transaction (an “Escrow Agent”), in each case to be made without further consent of or notice to Genentech, with any such disclosure of Confidential Information occurring solely to the extent a Transaction is
consummated and during the term of such Transaction (such disclosures, the “Disclosures”). 

  
 2 

 Under the foregoing premises, and by its acknowledgement and agreement below, Genentech hereby consents to
the Disclosures; provided that (a) any Confidential Information of Genentech disclosed to the Borrower, or to the Investor or the Escrow Agent pursuant to the Disclosures, is subject to written confidentiality agreements at least as
strict as those binding upon Curis in Section 12 of the License Agreement with respect to such Confidential Information; (b) the Investor and any Escrow Agent are permitted to use such Confidential Information solely for purposes of
considering the Transaction and, if the Transaction is consummated, for purposes of fulfilling their obligations and exercising their rights arising from the Transaction; and (c) the Investor and any Escrow Agent are prohibited from disclosing
such Confidential Information to any third party except to their employees, consultants, agents and representatives who need to know such Confidential Information in connection with the Transaction and who are bound by written confidentiality
agreements at least as strict as those binding upon Curis in Section 12 of the License Agreement with respect to such Confidential Information. 
 Payment Direction 
 We are hereby requesting that Genentech acknowledge and agree, by
execution below of this Letter Agreement, commencing after Genentech receives written notice from Curis that the Transaction has been executed, to pay any and all Subject Payments directly to the Escrow Agent specified in such notice, by deposit to
the account specified in such notice. Genentech shall make the Subject Payments in accordance with the foregoing unless and until otherwise directed by a written notice from the Escrow Agent or by a joint written notice from the Borrower and the
Investor. Any notices to Genentech under this paragraph will be effective five (5) business days after receipt by Genentech and shall be sent in accordance with Section 16.1 of the License Agreement; provided, however, the
copy of any such notice shall be sent to the attention of the Global Head, Alliance and Asset Management (in lieu of a copy to the Vice President, Business Development). 
 The Subject Payments and this payment direction expressly exclude (a) any amounts payable to Curis under Sections 8.4 and 8.7 of the License Agreement; (b) any interest payable with respect to
late payments under Section 9.3 of the License Agreement solely with respect to amounts payable under Sections 8.4 and 8.7 of the License Agreement; (c) any amounts payable under Section 9.4 of the License Agreement solely with
respect to amounts payable under Sections 8.4 and 8.7 of the License Agreement; and (d) any indemnity payments payable under Section 14.1(b) of the License Agreement solely with respect to Losses suffered by Curis with respect to amounts
payable under Sections 8.4 and 8.7 of the License Agreement, each of which shall continue to be paid directly to Curis. 

  
 3 

 Miscellaneous 
 Except as specifically amended or supplemented by this Letter Agreement, the terms and conditions of the License Agreement and any other agreements governing the use and disclosure of any Confidential
Information shall remain unchanged and in full force and effect. This Letter Agreement may be executed in counterparts, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument.

 [Remainder of this page intentionally left blank] 

  
 4 

 If the foregoing is acceptable to you, please sign and date this Letter Agreement in the space provided
below. 
 Sincerely, 
  

					
	CURIS ROYALTY LLC:
		
	By:	 	Curis, Inc., its managing member
			
		 	By:	 	

		 	Name:	 	Daniel R. Passeri
		 	Title:	 	President & CEO
	
	CURIS, INC.:
			
		 	By:	 	

		 	Name:	 	Daniel R. Passeri
		 	Title:	 	President & CEO

 Agreed to and accepted as of the date first set forth above: 

					
		
		 	GENENTECH, INC. 

			
		 	By:	 	

		 	Name:	 	STEVE KROGNES
		 	Title:	 	CFO

  
 5EX-10.33

 Exhibit 10.33 

Confidential Materials Omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.

 PURCHASE AGREEMENT 

  

 
 PURCHASE
AND SALE AGREEMENT 
 Dated as of December 11, 2012 

between 

CURIS, INC., 
 as Seller, 
 and 

CURIS ROYALTY LLC, 
 as Buyer 
  
  

 

 TABLE OF CONTENTS 

 

									
	 SECTION 1. DEFINITIONS AND RELATED
MATTERS
	  	 	1	  
				
		 	Section 1.1.	  	Defined Terms	  	 	1	  
		 	Section 1.2.	  	Other Interpretive Matters	  	 	2	  
		
	 SECTION 2. AGREEMENT TO PURCHASE AND
SELL
	  	 	2	  
				
		 	Section 2.1.	  	Purchase and Sale	  	 	2	  
		 	Section 2.2.	  	Purchase Price; Closing	  	 	2	  
		 	Section 2.3.	  	True Sale; Precautionary Security Interest; No Assumption of Obligations; No Recourse	  	 	2	  
		
	 SECTION 3. PAYMENT
	  	 	4	  
				
		 	Section 3.1.	  	Payments; Reimbursements; Exclusions	  	 	4	  
		
	 SECTION 4. REPRESENTATIONS AND WARRANTIES
	  	 	4	  
				
		 	Section 4.1.	  	Seller’s Representations and Warranties	  	 	4	  
		 	Section 4.2.	  	Additional Representations by Seller	  	 	6	  
		 	Section 4.3.	  	Buyer’s Representations and Warranties	  	 	6	  
		
	 SECTION 5. GENERAL COVENANTS
	  	 	7	  
				
		 	Section 5.1.	  	Covenants	  	 	7	  
		
	 SECTION 6. TERM
	  	 	9	  
				
		 	Section 6.1.	  	Duration of Agreement	  	 	9	  
		
	 SECTION 7. INDEMNIFICATION
	  	 	9	  
				
		 	Section 7.1.	  	Survival of Representations and Warranties	  	 	9	  
		 	Section 7.2.	  	Mutual Indemnification	  	 	9	  
		
	 SECTION 8. MISCELLANEOUS
	  	 	10	  
				
		 	Section 8.1.	  	Amendments, Waivers, etc.	  	 	10	  
		 	Section 8.2.	  	Successors and Assigns	  	 	10	  
		 	Section 8.3.	  	Binding Effect; Assignment	  	 	10	  
		 	Section 8.4.	  	Notices	  	 	10	  
		 	Section 8.5.	  	Costs and Expenses	  	 	10	  
		 	Section 8.6.	  	Execution in Counterparts; Integration	  	 	11	  
		 	Section 8.7.	  	Governing Law; Submission to Jurisdiction; Waiver of Jury Trial	  	 	11	  
		 	Section 8.8.	  	Entire Agreement	  	 	11	  
		 	Section 8.9.	  	Severability	  	 	11	  
		 	Section 8.10.	  	Time	  	 	11	  
		 	Section 8.11.	  	Relationship of the Parties	  	 	11	  
		
	 Exhibit A            License Agreement
	  			

  
 D-i

 THIS PURCHASE AND SALE
AGREEMENT dated as of December 11, 2012 (this “Agreement”) is by and between Curis, Inc. (the “Seller”) and Curis Royalty LLC, a Delaware limited liability company (the “Buyer”).

 RECITALS 
 A. Seller is entitled to receive certain royalties and other payments from Genentech, Inc. (“Genentech”), a Delaware corporation, under the Collaborative Research, Development and License
Agreement, dated as of June 11, 2003, by and between the Seller and Genentech, as amended from time to time (the “License Agreement”). 
 B. Buyer and Seller wish to enter into this Agreement to effect the sale and assignment by Seller to Buyer of a limited portion of payments to Seller under the License Agreement constituting the
Post-Closing Royalty Amounts (as defined below) on the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the premises and the mutual covenants set forth herein, the parties agree as follows: 
 SECTION 1.
DEFINITIONS AND RELATED MATTERS. 
 Section 1.1. Defined
Terms. In this Agreement, unless otherwise specified or defined herein: (a) capitalized terms are used as defined in the Credit Agreement dated as of November 27, 2012 (as amended or modified from time to time, the “Credit
Agreement”) among Buyer, Seller and Biopharma Secured Debt Fun II Sub, S.à.r.l., a Luxembourg limited liability company, as such agreement may be amended or modified from time to time; and (b) terms defined in Article 9 of the
UCC and not otherwise defined herein are used as defined in such Article 9. 
 In addition, the following term will have the
meaning specified below: 
 “Closing Date” means the date on which this Agreement becomes
effective in accordance with its terms, which is the date of this Agreement. 
 “Post-Closing Royalty
Amounts” means: (a) any and all royalty payments specified in Section 8.5 of the License Agreement paid or payable pursuant thereto after the Closing Date (including late payments thereof, if any); (b) any and all amounts
paid or payable pursuant to Section 9.4 of the License Agreement after the Closing Date with respect to the underpayment of any royalties payable under Section 8.5 of the License Agreement (excluding the out-of-pocket costs of the auditing
party in connection with any such audit that are payable by Genentech, if any); (c) any and all indemnity payments paid or payable pursuant to Section 14.1(b) of the License Agreement with respect to Losses (as defined in the License
Agreement) suffered by the Buyer after the Closing Date with respect to any amounts payable under Sections 8.5, 9.3 or 9.4 of the License Agreement; and (d) any interest paid or payable under Section 9.3 of the License Agreement after the
Closing Date with respect to the late payment of any of the foregoing amounts or interest thereon. 

  
 D-1

 Section 1.2. Other Interpretive Matters. In this Agreement, unless otherwise
specified: (a) references to any Section or Annex refer to such Section of, or Annex to, this Agreement, and references in any Section or definition to any subsection or clause refer to such subsection or clause of such Section or definition;
(b) “herein”, “hereof”, “hereto”, “hereunder” and similar terms refer to this Agreement as a whole and not to any particular provision of this Agreement;
(c) “including” means including without limitation, and other forms of the verb “to include” have correlative meanings; (d) the word “or” is not exclusive; and (e) captions are solely for
convenience of reference and shall not affect the meaning of this Agreement. 
 SECTION 2. AGREEMENT
TO PURCHASE AND SELL. 
 Section 2.1. Purchase and Sale.
On the terms and subject to the conditions set forth in this Agreement, and in consideration of the payment by Buyer to Seller of the entire Purchase Price (as defined below), Seller hereby agrees to sell, convey, transfer and assign to Buyer, and
Buyer hereby agrees to purchase and accept from Seller, on the Closing Date, all of Seller’s right, title and interest in and to the Post-Closing Royalty Amounts, free and clear of any and all Liens of any kind whatsoever. The sale, conveyance,
transfer, assignment and deliver of the Post-Closing Royalty Amounts by Seller to Buyer will be effected by Buyer and Seller executing the Bill of Sale. 
 Section 2.2. Purchase Price; Closing. The aggregate purchase price for the Post-Closing Royalty Amounts sold on the Closing Date shall be equal to Thirty Million Dollars ($30,000,000), which
amounts shall be payable by wire transfer of federal funds or other immediately available funds to Boston Private Bank & Trust, account number [**], routing number [**] (the “Purchase Price”). On the Closing Date,
(a) Seller and Buyer will execute, and deliver to the other party, the Bill of Sale, and (b) following Seller’s receipt of the Purchase Price, Seller will acknowledge receipt of payment of the Purchase Price from the Buyer.

 Section 2.3. True Sale; Precautionary Security Interest; No Assumption of Obligations; No Recourse. Seller and
Buyer intend and agree that the sale, conveyance, assignment and transfer of the Post-Closing Royalty Amounts shall constitute a true sale by Seller to Buyer of the Post-Closing Royalty Amounts that is absolute and irrevocable and that provides
Buyer with the full benefits and detriments of ownership of the Post-Closing Royalty Amounts (such that the Post-Closing Royalty Amounts would not be property of Seller’s estate in the event of Seller’s bankruptcy, insolvency or similar
proceeding), and neither Buyer nor Seller intends the transactions contemplated hereunder to be, or for any purpose to be characterized as, a financing transaction, borrowing or a loan from Buyer to Seller. Each of Seller and Buyer further agrees
that it will treat the sale of the Post-Closing Royalty Amounts as a sale of an “account” in accordance with the UCC. Seller disclaims any ownership interest in the Post-Closing Royalty Amounts upon execution of this Agreement and each of
Seller and Buyer waives any right to contest or otherwise assert that this Agreement is other than a true, absolute and irrevocable sale, conveyance, assignment and transfer by Seller to Buyer of the Post-Closing Royalty Amounts under applicable
law, which waiver will be enforceable against the applicable party hereto in any bankruptcy, insolvency or similar proceeding relating to such party. In view of the intention of Buyer and Seller that the sale of the Post-Closing Royalty amounts will
constitute a true sale thereof rather than a loan secured thereby or any other type of financial transaction, Seller hereby acknowledges and agrees that it will reflect in its books, 

  
 D-2

 
records, Tax returns and financial statements, as applicable, that the Post-Closing Royalty Amounts have been sold by Seller to Buyer and Buyer acknowledges and agrees that it will reflect in its
books, records, Tax returns and financial statements, as applicable, that the Post-Closing Royalty Amounts have been purchased by Buyer from Seller. Accordingly, the Seller hereby authorizes and consents to the Buyer filing one or more UCC financing
statements (and continuation statements with respect to such financing statements when applicable) or other instruments and notices, in such manner and in such jurisdictions as in Buyer’s determination may be necessary or appropriate to
evidence the purchase, acquisition and acceptance by Buyer of the Post-Closing Royalty Amounts hereunder and to perfect and maintain the perfection of Buyer’s ownership in the Post-Closing Royalty Amounts and the security interest in the
Post-Closing Royalty Amounts granted by Seller to Buyer pursuant to this Section 2.3. 
 Without limiting the
provisions of the foregoing paragraph of this Section 2.3, it is the intent and expectation of both Seller and Buyer that the sale, conveyance, assignment and transfer of the Post-Closing Royalty Amounts be a true, irrevocable and
absolute sale by Seller to Buyer for all purposes. Notwithstanding the foregoing, in an abundance of caution to address the possibility that, notwithstanding that Seller and Buyer expressly intend and expect for the sale, conveyance, assignment and
transfer of the Post-Closing Royalty Amounts hereunder to be a true and absolute sale and assignment for all purposes, in the event that such sale and assignment will be characterized as a loan or other financial accommodation and not a true sale or
such sale will for any reason be ineffective or unenforceable as such, as determined in a judicial, administrative or other proceeding (any of the foregoing being a “Recharacterization”), then this Agreement will be deemed to
constitute a “security agreement” under the UCC and other applicable law. For this purpose and without being in derogation of the intention of Seller and Buyer that the sale of the Post-Closing Royalty Amounts will constitute a true
sale thereof, effective as of the Closing Date, Seller does hereby grant to Buyer a continuing “security interest” (as such term is defined in the UCC) of first priority in all of Seller’s right, title and interest in, to and
under the Post-Closing Royalty Amounts, whether now or hereafter existing, and any and all “proceeds” thereof (as such term is defined in the UCC), in each case, for the benefit of Buyer as security for the prompt and complete
payment of a loan deemed to have been made in an amount equal to the Purchase Price together with the performance when due of all of Seller’s obligations now or hereafter existing under this Agreement, the Bill of Sale and any other document,
certificate or other instrument delivered in connection therewith, which security interest will, upon the filing of a duly prepared financing statement in the appropriate filing office, be perfected and prior to all other Liens thereon. Buyer will
have, in addition to the rights and remedies which it may have under this Agreement, all other rights and remedies provided to a secured creditor after default under the UCC and other applicable law, which rights and remedies will be cumulative.
Seller hereby authorizes Buyer, as secured party, to file the UCC financing statements contemplated hereby. In the case of any Recharacterization, each of Seller and Buyer represents and warrants as to itself that each remittance of Post-Closing
Royalty Amounts (or any portion thereof) or any other payment owed by Seller to Buyer under this Agreement, will have been in payment of a debt incurred by Seller in the ordinary course of business or financial affairs of Seller and Buyer, and made
in the ordinary course of business or financial affairs of Seller and Buyer. 
 Notwithstanding any provision in this Agreement
or any other writing to the contrary, Buyer is acquiring only the Post-Closing Royalty Amounts and is not assuming any liability or 

  
 D-3

 
obligation of the Seller of whatever nature, whether presently in existence or arising or asserted hereafter, whether under the License Agreement, any future licensing agreement or otherwise. All
such liabilities and obligations shall be retained by and remain obligations of the Seller. 
 Except as specifically provided
in this Agreement, the sale, conveyance, assignment and transfer of the Post-Closing Royalty Amounts to Buyer hereunder shall be without recourse to Seller. 
 SECTION 3. PAYMENT 
 Section 3.1.
Payments; Reimbursements; Exclusions. On or prior to the Closing Date, Seller shall direct Genentech in the Consent and Direction to promptly remit to the Escrow Account, following the Closing Date, any and all Post-Closing Royalty Amounts
directly to Boston Private Bank and Trust Company, as Escrow Agent, by deposit to the Escrow Account unless and until otherwise directed in writing by Escrow Agent or by a joint written instruction by the Buyer and Biopharma Secured Debt Fund II
Sub, S.à.r.l, as Lender. Additionally, pursuant to the Credit Agreement, if and to the extent any Post-Closing Royalty Amounts are received by Seller or Buyer (despite and in contradiction to the Consent and Direction and the Commencement
Notice), Seller or Buyer, as applicable, shall hold any and all such amounts in trust for the benefit of Biopharma Secured Debt Fund II Sub, S.à.r.l and shall promptly remit any and all such amounts to the Escrow Account. 

Pursuant to and as further described in the Credit Agreement, Seller will be reimbursed out of Post-Closing Royalty Amounts received for
any Escrow Agent Fees paid by Seller and any Indemnity Collection Costs actually incurred by Seller before any Adjusted Post-Closing Royalty Amounts are distributed by the Escrow Agent to the Residual Account. For the avoidance of doubt, the
Post-Closing Royalty Amounts exclude any amounts payable to Seller (a) under Sections 8.4 and 8.7 of the License Agreement (including late payments thereof, if any), (b) under Section 9.4 of the License Agreement with respect to the
underpayment of any amounts payable under Sections 8.4 or 8.7 of the License Agreement, (c) under Section 14.1(b) of the License Agreement with respect to Losses (as defined in the License Agreement) suffered by the Seller with respect to
any amounts payable under Sections 8.4 or 8.7 of the License Agreement and (d) under Section 9.3 of the License Agreement with respect to the late payment of any of the foregoing amounts or interest thereon, which, in each case, shall
continue to be paid by Genentech directly to the Seller pursuant to the License Agreement. 
 SECTION 4.
REPRESENTATIONS AND WARRANTIES. 
 Section 4.1. Seller’s
Representations and Warranties. Except as qualified by the exceptions set out in Schedule 4, Seller represents and warrants to Buyer hereunder as follows, which representations and warranties shall be deemed to be made on the Closing Date:

 (a) Corporate Existence and Power. Seller is a corporation, duly formed, validly existing and in good
standing under the laws of the State of Delaware, has the power and authority to own its properties and to carry on its business as now being and hereafter proposed to be conducted and is duly qualified and in good standing, and is authorized to do
business, in all jurisdictions in which the character of its properties or 

  
 D-4

 
the nature of its business requires such qualification or authorization, except for qualifications and authorizations the lack of which, singly or in the aggregate, has not had or would not
reasonably be expected to result in a Material Adverse Effect. 
 (b) Corporate Authorization, No
Contravention and Binding Effect. Its execution, delivery and performance of each Transaction Document to which it is a party and the creation of all security interests provided for herein (i) are within its powers, (ii) have been duly
authorized by all necessary corporate action, and (iii) do not contravene or constitute a default under: (A) any applicable law, rule or regulation, (B) its charter or by laws or (C) any material agreement, order or other
instrument to which it is a party or its property is subject. This Agreement and each of the closing documents have been duly authorized, executed and delivered by Seller and constitute Seller’s valid and binding obligation, enforceable against
Seller in accordance with their terms. 
 (c) No Consent Required. The execution, delivery and performance
in accordance with its terms by the Seller of this Agreement does not and (absent any change in any Applicable Law or any applicable Contract) will not (a) require any Governmental Approval or any other consent or approval to have been obtained
or any Governmental Registration to have been made, other than (i) Governmental Approvals and other consents and approvals and Governmental Registrations that have been obtained or made, as the case may be, are final and not subject to review
on appeal or to collateral attack, are in full force and effect and copies of which have been delivered to the Buyer and (ii) the filing of financing statements under the Code necessary and sufficient to perfect the security interests created
pursuant to this Agreement, or (b) violate, conflict with, result in a breach of, constitute a default under, require the consent or approval of any Person, or result in or require the creation of any Lien upon any assets of the Seller under,
(i) any Contract to which the Seller is a party or by which the Seller or any of its properties may be bound or (ii) any Applicable Law. 
 (d) Ownership. Seller owns legal and equitable title to the Post-Closing Royalty Amounts, free and clear of any and all Liens of any kind whatsoever. Pursuant to Section 2.1, all of
Seller’s right, title and interest in and to the Post-Closing Royalty Amounts shall be sold and transferred to Buyer, free and clear of any and all Liens of any kind whatsoever. Seller has not assigned and has not in any other way conveyed,
transferred or encumbered all or any portion of its right, title and interest to the License Agreement as it relates to any Post-Closing Royalty Amounts. On the Closing Date, upon payment of the Purchase Price and filings of the applicable UCC
financing statements to perfect the sale of the Post-Closing Royalty Amount as “accounts” under Section 9-102(a)(2) of the UCC, Buyer will acquire good and valid title in and to the Post-Closing Royalty Amounts, free and clear
of any and all Liens of any kind whatsoever. 
 (e) License Agreement. A true and correct copy of the
License Agreement, including all amendments, supplements or modifications thereto, is attached as Exhibit A. Seller represents that the License Agreement is in full force and effect, is a legal, valid and binding obligation of Seller and, to
the knowledge of Seller, enforceable against Seller in accordance with its terms subject to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the rights of creditors generally and to equitable principles. 

  
 D-5

 Section 4.2. Additional Representations by Seller. Seller further represents and
warrants to Buyer as of the Closing Date as follows: 
 (a) Perfection of Ownership Interest. Immediately
prior to the Closing Date, the Seller is the owner of all right, title and interest in and to the Post-Closing Royalty Amounts, free and clear of any and all Liens of any kind whatsoever. On the Closing Date, immediately following Seller’s sale
to Buyer of all of its right, title and interest in and to the Post-Closing Royalty Amounts, Buyer will own all right, title and interest in and to the Post-Closing Royalty Amounts, free and clear of any and all Liens of any kind whatsoever. Other
than the security interest or the ownership interest granted to Buyer pursuant to this Agreement, Seller has not pledged, assigned, sold or granted a security interest in, or otherwise conveyed, any Post-Closing Royalty Amounts. 

(b) Accuracy of Information. The Information furnished to the Buyer by or on behalf of the Seller on or prior to
the Closing Date did not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein not misleading in the light of the circumstances under which they were made,
provided, however, that in no event does the Seller make any representation as to the truth or accuracy of Information generated or disclosed by third parties, including Genentech. 

(b) Residency. Seller is a corporation organized under the laws of the State of Delaware, in the United States.

 (c) Not an Investment Company. Seller is not an “investment company” within the meaning of
the Investment Company Act of 1940, as amended from time to time, or any successor statute. 
 Section 4.3. Buyer’s
Representations and Warranties. Buyer represents and warrants to Seller as of the Closing Date as follows, and acknowledges that Seller is relying on such representations and warranties in entering into this Agreement: 

(a) Corporate Existence and Power. Buyer is a limited liability company, duly formed, validly existing and in good
standing under the laws of the State of Delaware, has the power and authority to enter into, execute, deliver and perform this Agreement and to perform all the obligations to be performed by it hereunder. 

(b) Corporate Authorization, Binding Effect and No Contravention. This Agreement has been duly authorized, executed
and delivered by the Buyer and constitutes Buyer’s valid and binding obligation, enforceable against Buyer in accordance with its terms. Its execution, delivery and performance of this Agreement (i) is within its powers, (ii) has been
duly authorized, executed and delivered by all necessary corporate action, (iii) does not contravene or constitute a default under: (A) any applicable law, rule or regulation, (B) its charter or by laws or limited liability company
agreement or (C) any material agreement, order or other instrument to which it is a party or its property is subject. 
 (c) No Consent Required. No consent, approval, license, order or authorization, registration, declaration or filing with or of any person is required by Buyer in connection with the execution and
delivery by Buyer of this Agreement and the Buyer’s closing documents, the performance by it of its obligations under this Agreement and the closing documents or the consummation of any of the transactions contemplated hereby or thereby.

  
 D-6

 SECTION 5. GENERAL COVENANTS. 

Section 5.1. Covenants. Seller hereby covenants and agrees to comply with the following covenants and agreements, unless Buyer
shall otherwise consent: 
 (a) Notices. Subject to and in accordance with the confidentiality obligations
and disclosure provisions set forth in the License Agreement and the Consent and Direction, Seller will promptly notify Buyer and provide a description in writing of each of the following: 

(i) Defaults. Any event which to Seller’s knowledge is a default by Genentech under the License Agreement or
termination by Genentech under the License Agreement that relates to, affects or could reasonably be expected to materially adversely affect (x) any Post-Closing Royalty Amount (or portion thereof) or (y) any of Buyer’s rights or
benefits under this Agreement; 
 (ii) Litigation. The institution of any litigation, arbitration
proceeding or governmental proceeding in respect of, affecting, or that could reasonably be expected to affect (x) any Post-Closing Royalty Amounts (or portion thereof) or (y) any of Buyer’s rights or benefits under this Agreement,
and any judgment or settlement with respect to any such litigation; and 
 (iii) Correspondence under the
License Agreement. The receipt by Seller of any material written notice, report, or correspondence under the License Agreement with respect to any Post-Closing Royalty Amount (or portion thereof), and Seller shall inform Buyer of the receipt and
the substance of such notice, report or correspondence, together with a copy of such notice, report or correspondence, which Buyer shall receive subject to the confidentiality obligations set forth in Section 5.1(c). 

(b) Conduct of Business. Seller will perform all actions necessary to remain duly incorporated, validly existing
and in good standing in its jurisdiction of incorporation and to maintain all requisite authority to conduct its business in each jurisdiction where such authority is necessary, except where the failure to obtain such authority could not reasonably
be expected to have a Material Adverse Effect. Seller shall use commercially reasonable efforts to fully perform and fulfill each of its obligations under the License Agreement in accordance with the terms thereof and to maintain its rights under
the License Agreement in full force and effect. Seller shall use commercially reasonable efforts: (i) to fully enforce its rights to receive all Post-Closing 

  
 D-7

 
Royalty Amounts from Genentech under the License Agreement; and (ii) to enforce all of its rights and remedies under the License Agreement upon the occurrence of a material breach of the
License Agreement by Genentech with respect to any Post-Closing Royalty Amount (or portion thereof), which is not cured within the period provided therein, if any. 

(c) Confidentiality. 
 (i) All information furnished by Buyer to Seller or by Seller to Buyer in connection with this Agreement and the transactions contemplated hereby, as well as the terms, conditions and provisions of this
Agreement (collectively the “Confidential Information”), shall be kept confidential by the recipient thereof and shall be used by such recipient only in connection with this Agreement and the transactions contemplated hereby, except
in connection with the enforcement of rights under this Agreement and except to the extent that such information (i) is already known by the party to whom the information is disclosed, (ii) is publicly known at the time the information is
disclosed from a source other than the recipient hereunder and such source was under no confidentiality obligation with respect thereto, (iii) is or thereafter becomes lawfully obtainable from other sources who are not under a confidentiality
obligation with respect thereto; or (iv) is required by law to be disclosed by recipient or has been requested by a governmental or regulatory authority having jurisdiction over recipient; provided, however, that each party hereto shall be
permitted to use the Confidential Information in connection with the Credit Agreement, Escrow Agreement and the other Loan Documents and to disclose the Confidential Information to Biopharma Secured Debt Fund II Sub, S.à.r.l pursuant to and
in accordance with the Credit Agreement (including Section 5.04 thereof) and to Biopharma Secured Debt Fund II Sub, S.à.r.l and the Escrow Agent pursuant to and in accordance with the Escrow Agreement. 

(ii) The obligations of this Section 5.1(c) shall survive for [**] years after the termination or expiration
of this Agreement. 
 (iii) Notwithstanding the foregoing, if any court or governmental agency or authority
requests or requires a party (the “Recipient”) to disclose any of the other party’s Confidential Information, such party shall, to the extent permissible, provide the other party (the “Originator”) with prompt
notice of such request or requirement. The Originator may, at the Originator’s expense, either seek appropriate protective relief from all or part of such request or requirement or waive the Recipient’s compliance with the provisions of
this Agreement with respect to all or part of such request or requirement. At the Originator’s expense, the Recipient shall cooperate with the Originator on a commercially reasonable basis in attempting to obtain any such protective relief the
Originator chooses to seek. Notwithstanding the foregoing, the Recipient may disclose that portion of the Originator’s Confidential Information which its legal counselor advises the Recipient that the Recipient is legally compelled to disclose
to such court, agency, or authority at the same time providing, to the extent permissible by law, the 

  
 D-8

 
Originator with a copy of the Confidential Information so disclosed; provided, however, that the Recipient shall, at the Originator’s expense, use those commercially reasonable efforts
requested of it by the Originator in attempting to obtain confidential treatment (such as a protective order or similar assurance) for such Confidential Information as so disclosed. 

(d) Buyer’s Audit Right. To the extent that Buyer believes in good faith that Genentech has underpaid any
Post-Closing Royalty Amounts, Buyer shall, in writing, notify Seller of such belief, including the calendar quarter in question, and shall request that Seller initiate an audit for the fiscal year that includes such calendar quarter pursuant to
Section 9.4 of the License Agreement to confirm the accuracy of such Post-Closing Royalty Amounts, and Seller shall initiate such audit pursuant to Section 9.4 of the License Agreement; provided that, in such case, (a) the Lender
shall reimburse Seller for all expenses of such audit actually incurred by Seller pursuant to Section 9.4 of the License Agreement (to the extent such expenses are not paid by Genentech) and (b) the Seller shall direct Genentech to, or to
the extent such funds are received by the Seller, the Seller shall, promptly remit into the Company Account the amount of any underpayments revealed by such audit, plus interest, provided however, that any shortfall in Post-Closing Royalty Amounts
discovered and recovered by Seller as a result of an audit shall, first be paid to Buyer or Seller (whichever incurred the expenses in connection with such audit) for the expenses incurred in connection with such audit and only the balance recovered
shall be included in Post-Closing Royalty Amounts and paid to Buyer. 
 SECTION 6. TERM. 

Section 6.1. Duration of Agreement. This Agreement shall commence as of the Closing Date and will continue in full force and
effect until all of Buyer’s right to receive any payments on account of the Post-Closing Royalty Amounts set forth in this Agreement and all other amounts to which Buyer may be entitled to receive as payment hereunder have expired (the
“Term”). Upon expiration of the Term, this Agreement will terminate, following which Buyer shall file UCC termination statements with respect to the interest granted by Seller pursuant to Section 2.3 of this Agreement.

 SECTION 7. INDEMNIFICATION. 
 Section 7.1. Survival of Representations and Warranties. All representations and warranties of the parties to this Agreement shall survive the execution and delivery of this Agreement. Any
investigation or other examination that may have been made or may be made at any time by or on behalf of the party to whom representations and warranties are made shall not limit, diminish or in any way affect the representations and warranties in
this Agreement. 
 Section 7.2. Mutual Indemnification. Seller hereby indemnifies and holds Buyer and any director,
employee, agent and affiliate thereof harmless from any damage, loss, cost, liability, action, cause of action, demand or expense including reasonable attorney’s fees (“Loss”) resulting from (i) any breach of a
representation or warranty of Seller contained herein, or (ii) the breach by Seller of any covenant or obligation contained in this Agreement or any agreement entered into by Seller in connection herewith or pursuant hereto, or (iii) any
Lien on 

  
 D-9

 
the Post-Closing Royalty Amounts existing prior to the Closing Date and not disclosed in the Schedule of Exceptions, whether choate or inchoate. Buyer hereby indemnifies and holds Seller any
trustee, director, employee, agent and affiliate thereof harmless from any Loss resulting from (i) any breach of a representation or warranty of Buyer contained herein, or (ii) the breach by Buyer of this Agreement or any agreement entered
into by Buyer in connection herewith or pursuant hereto. 
 SECTION 8. MISCELLANEOUS. 

Section 8.1. Amendments, Waivers, etc. This Agreement may be amended, modified or supplemented only by a written agreement
signed by Buyer and Seller. Any waiver of, or consent to depart from, the requirements of any provision of this Agreement shall be effective only if it is in writing and signed by the party giving it, and only in the specific instance and for the
specific purpose for which it has been given. No failure on the part of any party to exercise, and no delay in exercising, any right under this Agreement shall operate as a waiver of such right. No single or partial exercise of any such right shall
preclude any other or further exercise of such right or the exercise of any other right. 
 Section 8.2. Successors and
Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of Seller and Buyer. This Agreement may not be assigned in whole or in part by Seller or Buyer without the prior written consent of
the other party. Any assignment not in accordance with the foregoing shall be void. 
 Section 8.3. Binding Effect;
Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. 
 Section 8.4. Notices. All notices, consents, waivers and other communications hereunder shall be in writing and shall be delivered in person, sent by overnight courier, facsimile transmission
or posted by registered or certified mail, return receipt requested, with postage prepaid, addressed as follows, or to such other addresses as Buyer and Seller may from time to time designate by notice as provided herein: 

(i) If to Buyer: 
 Curis Royalty LLC 
 4 Maguire Road 

Lexington, MA 02412 
 Attn: Secretary 
 (ii) If to Seller: 

Curis, Inc. 
 4
Maguire Road 
 Lexington, MA 02412 
 Attn: Chief Financial Officer 
 Any such notice shall be deemed given when
actually received. 
 Section 8.5. Costs and Expenses. Seller and Buyer shall be responsible for and bear all of
their own costs and expenses with regard to the consummation of the transaction contemplated 

  
 D-10

 
hereby. Each party represents and warrants to the other that the other party will not be liable for any brokerage commission, finder’s fee or other like payment in connection with the
transactions contemplated hereby because of any action taken by, or agreement or understanding reached by, that party. 

Section 8.6. Execution in Counterparts; Integration. This Agreement may be executed in two or more counterparts, each of
which shall be an original, but all of which together shall constitute one and the same instrument. 
 Section 8.7.
Governing Law; Submission to Jurisdiction; Waiver of Jury Trial. THE RIGHTS AND DUTIES OF THE PARTIES UNDER
THIS AGREEMENT SHALL BE GOVERNED BY THE LAW OF THE STATE OF
NEW YORK. BUYER AND seller EACH AGREE THAT ANY JUDICIAL PROCEEDING BROUGHT
AGAINST IT WITH RESPECT TO ANY CLAIM RELATED TO A TRANSACTION
DOCUMENT MAY BE BROUGHT IN ANY COURT OF COMPETENT JURISDICTION IN THE
CITY OF NEW YORK AND IRREVOCABLY WAIVES ANY OBJECTION IT MAY NOW
OR HEREAFTER HAVE AS TO THE VENUE OF ANY SUCH PROCEEDING BROUGHT
IN SUCH A COURT OR THAT SUCH A COURT IS AN INCONVENIENT
FORUM. EACH PARTY HERETO WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS
THAT SERVICE OF PROCESS UPON IT MAY BE MADE BY CERTIFIED OR
REGISTERED MAIL, RETURN RECEIPT REQUESTED, AT ITS ADDRESS SPECIFIED OR DETERMINED
IN ACCORDANCE WITH THE PROVISIONS OF SECTION 8.4, AND SERVICE SO MADE
SHALL BE DEEMED COMPLETED ON THE THIRD BUSINESS DAY AFTER SUCH
SERVICE IS DEPOSITED IN THE MAIL. ANY JUDICIAL PROCEEDING BY ANY
PARTY TO THIS AGREEMENT INVOLVING ANY CLAIM RELATED TO A TRANSACTION
DOCUMENT SHALL BE BROUGHT ONLY IN A COURT LOCATED IN THE CITY
AND STATE OF NEW YORK. EACH PARTY HERETO HEREBY WAIVE TRIAL BY JURY IN ANY JUDICIAL PROCEEDING TO WHICH THEY ARE PARTIES INVOLVING ANY CLAIM RELATED TO A TRANSACTION
DOCUMENT. 
 Section 8.8. Entire Agreement. This Agreement, together with the Exhibits and Schedules to this
Agreement (which are incorporated herein by reference), supersedes any other agreement, whether written or oral, that may have been made or entered into by the parties hereto relating to the matters contemplated hereby and constitutes the entire
agreement of the parties hereto with respect to the subject matter hereof. 
 Section 8.9. Severability. If any
provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect. 
 Section 8.10. Time. Time is of the essence of this Agreement and each of its provisions. 
 Section 8.11. Relationship of the Parties. This Agreement is not a partnership agreement and nothing in this Agreement shall be construed to establish a relationship of co-partners or joint
venturers between Seller and Buyer. 
 [SIGNATURE PAGE TO FOLLOW]

  
 D-11

 IN WITNESS WHEREOF, the parties have caused
this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first above written. 
  

			
	“SELLER”
	
	CURIS, INC.
		
	By	 	
	Name:	 	 /s/ Daniel R. Passeri

	Title:	 	President and Chief Executive Officer
	
	“BUYER”
	
	CURIS ROYALTY, LLC.
		
	By	 	
	Name:	 	 /s/ Daniel R. Passeri

	Title:	 	President and Chief Executive Officer

  
 D-S-1

 EXHIBIT A 

LICENSE AGREEMENT 
 Incorporated by reference to Exhibit 10.1 to the Company’s Form 10-Q for the fiscal period ended September 30, 2012 as filed with the Securities and Exchange Commission on November 6, 2012.

  
 D-Exh. A-1

 EXHIBIT B 

BILL OF SALE 

  
 D-Exh. B-1

 This Bill of Sale (“Bill of Sale”) dated December 11, 2012 is executed and delivered
by Curis, Inc., a Delaware corporation (the “Seller”), to Curis Royalty LLC a Delaware limited liability company (the “Buyer”). All capitalized words and terms used in this Bill of Sale and not defined herein shall
have the respective meanings ascribed to them in the Asset Purchase Agreement of even date herewith between the Seller and the Buyer (the “Asset Purchase Agreement”). 

WHEREAS, pursuant to the Asset Purchase Agreement, the Seller has agreed to sell, transfer, convey, assign and deliver to the Buyer the
Post-Closing Royalty Amounts; 
 NOW, THEREFORE, in consideration of the mutual promises set forth in the Agreement and other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Seller hereby agrees as follows: 
  

	 	1.	The Seller hereby sells, transfers, conveys, assigns and delivers to the Buyer, and the Buyer hereby purchases and receives, to have and to hold in accordance with the
Asset Purchase Agreement and this Bill of Sale, all of the Seller’s right, title and interest in, to and under all of the Post-Closing Royalty Amounts. 

 

	 	2.	The Buyer hereby acknowledges that the sale of the Post-Closing Royalty Amounts by the Seller to the Buyer under the Asset Purchase Agreement shall be without recourse
to the Seller except as specifically provided therein. The Seller and the Buyer intend and agree that such sale, conveyance, assignment and transfer of the Post-Closing Royalty Amounts shall constitute a true sale by the Seller to the Buyer of the
Post-Closing Royalty Amounts that is absolute and irrevocable and that provides the Buyer with the full benefits and detriments of ownership of the Post-Closing Royalty Amounts (such that the Post-Closing Royalty Amounts would not be property of the
Seller’s estate in the event of the Seller’s bankruptcy, insolvency or similar proceeding), and neither the Buyer nor the Seller intends the transactions contemplated hereunder to be, or for any purpose to be characterized as, a financing
transaction, borrowing or a loan from the Buyer to the Seller. 

  

	 	3.	The Seller hereby covenants that, at any time or from time to time after the date hereof, at the Buyer’s reasonable request and without further consideration, the
Seller will execute and deliver to the Buyer such other instruments of sale, transfer, conveyance and assignment as the Buyer may reasonably deem necessary to sell, transfer, convey, assign and deliver to the Buyer, and to confirm the Buyer’s
title to, all of the Seller’s right, title and interest in, to and under the Post-Closing Royalty Amounts. 

  

	 	4.	The Seller does hereby irrevocably constitute and appoint the Buyer, its successors and assigns, its true and lawful attorney, with full power of substitution, in its
name or otherwise, and on behalf of the Seller, or for its own use, to claim, demand, collect and receive in accordance with the Asset Purchase Agreement any and all of the Post-Closing Royalty Amounts. The Seller further authorizes the Buyer to
file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Seller as the seller and the Buyer as the buyer. 

  
 D-Exh. B-2

	 	5.	The Seller, by its execution of this Bill of Sale, and the Buyer, by its acceptance of this Bill of Sale, each hereby acknowledges and agrees that neither the
representations and warranties nor the rights, remedies or obligations of any party under the Asset Purchase Agreement shall be deemed to be enlarged, modified or altered in any way by this instrument except as specifically provided in Sections
3 and 4 hereof. 

  

	 	6.	This Bill of Sale will be binding upon and inure to the benefit of the Seller, the Buyer and their respective successors and assigns under the Asset Purchase Agreement,
for the uses and purposes set forth and referred to above, effective immediately upon its delivery to the Buyer. 

IN WITNESS WHEREOF, the Seller and the Buyer have caused this instrument to be duly executed under seal as of and on the date first above
written. 
  

			
	Curis, Inc.
		
	By:	 	 /s/ Daniel R. Passeri

		
	Title:	 	 President and Chief Executive Officer

  

			
	ACCEPTED:
	
	Curis Royalty LLC
		
	By: 	 	 /s/ Daniel R. Passeri

		
		 	 President and Chief Executive Officer

 [Signature Page to Curis, Inc. Bill of Sale] 

  
 D-Exh. B-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]